In July 2014, ASCO President Peter Paul Yu, MD, FACP, FASCO, wrote a lengthy letter to the CEO of the U.S. Pharmacopeial Convention (USP), commenting on the proposal for Chapter <800> regulations, saying “it is not evidence-based and is fundamentally flawed” and urging USP to “engage with ASCO in a more collaborative process before finalizing recommendations in this area.”
In response, USP revised its recommendations and offered them for public comment until May 31. For more information, go to http://www.usp.org/usp-nf/notices/general-chapter-hazardous-drugs-handling-healthcare-settings.
To download the proposed Chapter <800> revisions, go to www.usp.org/sites/default/files/usp_pdf/EN/m7808.pdf.
To read Dr. Yu’s letter, go to www.asco.org/sites/www.asco.org/files/asco_usp_800_comments_final-c-c.pdf. ■
In March 2013, 60 Minutes aired a devastating piece about a Massachusetts compounding center that shipped an injectable steroid contaminated with fungus. One of the many ripple effects from this story of horrendous patient suffering was felt in Maryland, where it sparked legislative action in the...